Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii

Pharmacotherapy

Volumn 27, Issue 7, 2007, Pages 980-987

  Schafer, Jason J ^a,b   Goff, Debra A ^a   Stevenson, Kurt B ^a   Mangino, Julie E ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b St Margaret Memorial Hospital   (United States)

Author keywords

Bacteremia; Multidrug resistant Acinetobacter baumannii; Tigecycline; VAP; Ventilator associated pneumonia

Indexed keywords

COLISTIMETHATE; IMIPENEM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT FAILURE; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 34250896679     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.7.980     Document Type: Article

References (21)

1. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9.
2. Maslow JN, Glaze T, Adams P, et al. Concurrent outbreak of multi-drug resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital. Infect Control Hosp Epidemiol 2005;26:69-75.
3. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002;162:1515-20.
4. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003;36:1268-74.
5. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1119-21.
6. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41:S303-14.
7. Wyeth Pharmaceuticals. Tygacil (tigecycline) package insert. Madison, NJ; 2005.
8. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48:4479-81.
9. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41:S354-67.
10. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41:S341-53.
11. American Thoracic Society. Guidelines for the management of adults with hospital acquired, ventilator associated, and healthcare associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
12. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia: Saunders 1964:50-64.
13. Fritsche TR, Sader SH, Stilwell MG, et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005;52:187-93.
14. Bouchillon SK, Hoban Dj, Johnson BM, et al. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program, 2004). Diagn Microbiol Infect Dis 2005;52:173-9.
15. Monarch Pharmaceuticals. Coly-Mycin (colistimethate) package insert. Bristol, TN; 2005.
16. Falagas ME. Toxicity of polymixins: a systematic review of the evidence from old and recent studies [online exclusive article]. Crit Care 2006;10:R27. Available from http://ccforum.com/content/10/1/R27.
17. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmocother 1999;33:960-7.
18. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9.
19. Conte JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. J Antimicrob Chemother 2005;25:523-9.
20. Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479-87.
21. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31.